Leaps by Bayer backs a protein engineering startup taking on Aimmune — and Nestlé — in peanut allergy

Amber Tong

Little capsules of peanut powder drove Nestlé’s $2.6 billion buyout of Aimmune. Now, with $40 million in new funding, a fledgling biotech is promising …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Leaps by Bayer backs a protein engineering startup taking on Aimmune — and Nestlé — in peanut allergy

Amber Tong

Sign up to read this article for free.

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Bristol Myers sues the federal government over 340B, following other drugmakers

Leaps by Bay­er backs a pro­tein en­gi­neer­ing start­up tak­ing on Aim­mune — and Nestlé — in peanut al­ler­gy

Amber Tong

Sign up to read this article for free.

more like this

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Leaps by Bayer backs a protein engineering startup taking on Aimmune — and Nestlé — in peanut allergy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Bristol Myers sues the federal government over 340B, following other drugmakers